Adherence, Medication, Hypertension
Conditions
Keywords
Blood pressure, Antihypertensive treatment, Adherence, Biomarker, Urine, HPLC-MS/MS
Brief summary
Non-adherence to antihypertensive treatment is one of the leading causes of suboptimal blood pressure control and translates into increased risk of cardiovascular morbidity and mortality. Currently, there is no effective intervention for therapeutic non-adherence. Our project will assess whether high performance liquid chromatography mass spectrometry (HPLC-MS/MS)-guided intervention (providing patients with information on the results of their HPLC-MS/MS-based urine analysis combined with targeting the main reason for non-adherence) leads to an improvement in blood pressure control, adherence and a reduction in healthcare costs. Our multicentre prospective randomised controlled trial consists of 6 stages (screening, recruitment, baseline phenotype assessment, intervention, short-term and long-term outcome visits). The study will fill in an important gap in knowledge on management of blood pressure in non-adherent hypertensive patients beyond the initial diagnostic step. It will also inform the development of a cost-effective model for the management of non-adherence in chronic disorders that require long-term drug therapy.
Detailed description
Non-adherence to antihypertensive treatment is one of the leading causes of suboptimal blood pressure control and translates into increased risk of cardiovascular morbidity and mortality. Currently, there is no effective intervention for therapeutic non-adherence. An ultra-sensitive and highly specific biochemical assay has been developed to detect urinary biomarkers of antihypertensive treatment. The high performance liquid chromatography mass spectrometry (HPLC-MS/MS)-based assay screens spot urine samples for the presence of 40 commonly prescribed blood pressure lowering medications. The results of the test provide a clinician with information on the presence/absence of prescribed antihypertensive drugs or/and their metabolites in urine - a direct confirmation of therapeutic adherence/non-adherence. The study is a prospective multi-centre randomised controlled trial to examine if HPLC-MS/MS-guided intervention is superior to standard clinical care in improving clinical, behavioural and health-economy outcomes in hypertensive patients who are non-adherent to antihypertensive treatment. Patient adherence to antihypertensive treatment will be determined at baseline. Non-adherent hypertensive patients at baseline will be randomised in a 1:1 ration to either usual clinical care plus HPLC-MS/MS-guided intervention (Arm A) or usual clinical care only (Arm B). The study also evaluates a cohort of patients who are adherent to antihypertensive treatment at baseline. Those adherent hypertensive patients will receive the usual clinical care (Arm C). The main purpose of involving this group of patients is to blind the clinical research staff to the adherence status of those patients randomised receiving standard care alone, to prevent introducing any bias in treating non-adherent patients.
Interventions
OTHERHPLC-MS/MS-guided intervention
The HPLC-MS/MS-guided intervention consists of providing partially or totally non-adherent hypertensive patients with information on the results of their HPLC-MS/MS-based urine analysis combined with tailored targeting of the main reason(s) for the deviation from the prescribed antihypertensive treatment
OTHERStandard care
Standard care for hypertensive patients
Sponsors
British Heart Foundation
Manchester Academic Health Science Centre
Omron Healthcare Co., Ltd.
University of Manchester
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Masking description
Participants and clinicians will initially be blinded to the result of the baseline (at trial entry) HPLC-MS/MS based urine test to determine the participant adherence to antihypertensive treatment. Non-adherent patients allocated to Arm A will be un-blinded at the stage of visit 3 where the results of their HPLC-MS/MS urine test will be revealed to them as a part of HPLC-MS/MS-guided intervention. The doctor will also require un-blinding to provide the required intervention. However, during further study visits the research personnel will remain blinded as to the adherence status of these patients, the results of their HPLC-MS/MS-based analysis and the treatment allocation. The doctor who delivers the intervention will not be involved in collecting clinical information necessary to define outcomes during appointments 4 and 5. Hypertensive patients randomised to Arms B and C will remain blinded to the results of their HPLC-MS/MS-based urine test throughout all stages of the study.
Intervention model description
Multi-center randomised controlled trial
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Male or female aged 18 years or above * Patients previously diagnosed with and pharmacologically managed for hypertension * Patients with antihypertensive treatment with at least two antihypertensive medications * Patients have full capability of providing informed consent
Exclusion criteria
* Patients with recent history of admission to the hospital relating to their hypertension or treatment with anti-hypertensive medications (\<2 weeks) (i) * Patient refusal for 7-day home-based blood pressure monitoring (7-HBBPM) * Self-reported pregnancy or breastfeeding * Female patients planning to conceive within the next 6 months (i) Including admission to A&E
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in Clinic systolic blood pressure | visit 4 (short term follow-up; approx. 3 months post intervention, when feasible to conduct) | Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of systolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in clinic systolic blood pressure | visit 5 (long term follow-up; ~4.5 months post intervention, when feasible to conduct) | Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of systolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit |
| Change in clinic diastolic blood pressure | visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct) | Blood pressure measurements will be taken after 5 minutes of rest in a sitting position with an electronic digital Omron monitor and the cuff size adjusted to the arm circumference as per international guidelines. Three measurements of diastolic blood pressure will be taken in a row (separated by approximately 1 minute interval) and recorded at every visit |
| Change in home blood pressure | visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct) | This measurement will be conducted using oscillometric Omron monitors. Patients will be handed the monitors by the research nurses at each visit and will be provided instructions to use the Omron monitor. While all blood pressure measurements will be stored automatically on the monitors, patients will be also asked to keep a written record on paper (to avoid loss of data in case a monitor stops working or goes out of order). |
| Change in urinary albumin / creatinine ratio | visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct) | Urinary albumin / creatinine ratio is a urinary marker of target organ damage. |
| Changes in health economy parameters | visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct) | Health economy parameters (collected via questionnaires) will be calculated over the study time horizon to determine total costs of clinical/social care |
| Change in biochemical adherence of patients | visit 2 (~3 weeks post recruitment, when feasible to conduct) | HPLC-MS/MS test will determine the numbers and list of antihypertensive drugs detected in the patient urine sample and this will be compared to the patient prescription |
Other
| Measure | Time frame | Description |
|---|---|---|
| Changes in psychological profile | visit 4 (short term follow-up; ~3 months post intervention, when feasible to conduct) | Psychological questionnaires assessing participants perspectives of treatment will be completed by patient when attending clinic visit 1, 4 and 5 |
Countries
United Kingdom
Outcome results
None listed